Unlocking the potential of fungi: the QuantFung project by Büttel, Zsófia et al.
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
General rights 
Copyright and moral rights for the publications made accessible in the public portal are retained by the authors and/or other copyright owners 
and it is a condition of accessing publications that users recognise and abide by the legal requirements associated with these rights. 
 
• Users may download and print one copy of any publication from the public portal for the purpose of private study or research. 
• You may not further distribute the material or use it for any profit-making activity or commercial gain 
• You may freely distribute the URL identifying the publication in the public portal  
 
If you believe that this document breaches copyright please contact us providing details, and we will remove access to the work immediately 
and investigate your claim. 
   
 
Downloaded from orbit.dtu.dk on: Nov 08, 2017
Unlocking the potential of fungi: the QuantFung project
Büttel, Zsófia ; Díaz, Rafael ; Dirnberger, Benedict ; Flak, Michal ; Grijseels, Sietske; Kwon, Min Jin ;
Froslev Nielsen, Jens Christian ; Nygård, Yvonne ; Phule, Pradeep ; Pohl, Carsten ; Prigent, Sylvain ;
Randelovic, Milica; Schütze, Tabea ; Troppens, Danielle ; Viggiano, Annarita
Published in:
Fungal Biology and Biotechnology
Link to article, DOI:
10.1186/s40694-015-0016-0
Publication date:
2015
Document Version
Publisher's PDF, also known as Version of record
Link back to DTU Orbit
Citation (APA):
Büttel, Z., Díaz, R., Dirnberger, B., Flak, M., Grijseels, S., Kwon, M. J., ... Viggiano, A. (2015). Unlocking the
potential of fungi: the QuantFung project. Fungal Biology and Biotechnology, 2, [6]. DOI: 10.1186/s40694-015-
0016-0
Büttel et al. Fungal Biol Biotechnol  (2015) 2:6 
DOI 10.1186/s40694-015-0016-0
COMMENTARY
Unlocking the potential of fungi: the 
QuantFung project
Zsófia Büttel1, Rafael Díaz2, Benedict Dirnberger3, Michal Flak4, Sietske Grijseels5, Min Jin Kwon6, 
Jens Christian Froslev Nielsen7, Yvonne Nygård1, Pradeep Phule8, Carsten Pohl1, Sylvain Prigent7, 
Milica Randelovic5, Tabea Schütze6*, Danielle Troppens3 and Annarita Viggiano1
© 2015 Büttel et al. This article is distributed under the terms of the Creative Commons Attribution 4.0 International License 
(http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, 
provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, 
and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/
publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.
Background
The crisis of antibiotic resistance has been much dis-
cussed in recent decades within research communities 
and also in public. However, options to slow down the 
spread of resistance and the opportunities to discover 
new antimicrobial agents seem to be limited at present. 
Can we, by unlocking the hidden potential of fungi, attain 
new means to gain advantage in this battle?
Since the discovery and global use of the first fungal-
derived antibiotic, penicillin, resistance emerged. As new 
and larger quantities of antibiotics were introduced to 
the market, the more rapidly resistance was observed. 
This development was fostered by substantial over-use 
and misuse of antimicrobial substances in the treatment 
of human diseases, as well as their concurrent introduc-
tion in agriculture and veterinary settings. In addition to 
the prominent examples of bacteria, antimicrobial resist-
ance is also advancing in causal agents of notorious infec-
tious diseases such as malaria (a parasite), influenza and 
HIV (viruses), candidiasis and candidaemia (fungi), all of 
them posing a major threat to the public health, that col-
lectively cause hundreds of thousands deaths every year.
Especially in recent years, national and international 
programmes and campaigns have been initiated to raise 
the public awareness on antibiotic resistance. The World 
Health Organization is monitoring the use of antibiot-
ics and the emergence of resistant microbes, especially 
in countries where surveillance is virtually non-existent. 
Likewise, in Europe, US or Australia, where antibiotic 
usage is already more restricted as a response to concerns 
about drug resistance, public campaigns such as the 
“European Antibiotic Awareness Day”, “Get Smart about 
Antibiotics” or “National Antimicrobial Resistance Strat-
egy” respectively urge for a more sensible and careful use 
of antibiotics.
In addition to raising public awareness, the US and 
Europe are joining forces to encourage and renew efforts 
into research for novel antimicrobial substances and tar-
gets. This has been hampered by the decreasing interest 
of the pharmaceutical sector to invest in the develop-
ment and testing of drugs that are perceived as unprof-
itable by virtue of a limited financial market and other 
costs such as to be ineffective incentives. The problem 
was summarized in a comment in Nature by Cooper and 
Shlaes [1] (“Fix the antibiotics pipeline”) and is described 
in more detail in Shlaes’s book “Antibiotics: The Per-
fect Storm” [2], illustrating the requirement for new 
approaches to tackle microbial diseases by pointing out 
the steady decline in the number of new antimicrobial 
drugs entering the market and the dramatic increase of 
resistant bacteria. One of the EU/US joined task forces, 
the Transatlantic Task Force on Antimicrobial Resistance 
(TATFAR) that started in 2009, aims to facilitate finan-
cial benefits for research and improve the pipeline for the 
market approval of new drugs.
Around the time of these initiatives, at a conference in 
2011 on synthetic biology, held in St. Feliu in Spain, sci-
entists devoted to fungal research discussed the great 
potential of fungi to produce natural products and how 
little we still knew about those products. It had not been 
long before that the genomes of two biotechnologically 
relevant fungi, Penicillium chrysogenum (production of 
penicillin) [3] and Aspergillus niger (production of citric 
acid) [4], had been published and gene clusters predicted 
to be involved in the synthesis of known and unknown 
secondary metabolites identified. It was clear that these 
fungi could potentially produce many more substances 
than those we were already using. Thus, there was a 
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demand for new manners to discover and induce produc-
tion of fungal metabolites. Therefore, a project proposal 
was written to intensify the efforts to find novel antimi-
crobial fungal products while also to provide the train-
ing framework to educate the future generation of young 
researchers.
The project was provided with €3.9 million (EU Grant 
number 607332) as a 4-year multi-partner initial training 
network (ITN), as part of the Marie-Curie Actions in the 
Seventh Framework Programme ‘People’ (FP7 people), 
and it started in October 2013. Its focus is “Quantitative 
Biology for Fungal Secondary Metabolite Producers”, or 
in short “QuantFung”. It involves seven universities and a 
research institute, one industrial company as a full part-
ner and three associated industry partners, and is located 
in five different countries. We, the fellows, were recruited 
as young researchers, eleven of us as early stage research-
ers (ESR) aiming for a PhD, and four of us as experienced 
researchers (ER) in postdoctoral positions. In the coming 
years, we envision to make a contribution to new meth-
ods for finding and producing novel bioactive molecules 
from fungi.
The fellows behind QuantFung
In order to be accepted for a position within an EU-
funded ITN, each fellow needed to fulfil eligibility crite-
ria. One condition was to move to a country not lived in 
during the past 3 years. Given this mobility rule, we fel-
lows come from 12 different nations and are working in 
5 different countries (Fig. 1). We all have different back-
grounds, scientifically, as well as culturally, allowing us to 
improve our scientific and networking skills. The ITN is 
an excellent way of training our communication skills as 
well as finding common ground for collaborations.
In addition to equipping us with the skills to fulfil our 
tasks within the ITN, the network provides a wide range 
of training possibilities and serves as a bridge between 
industry and academia. The consortium organizes work-
shops in different disciplines: In the first year of Quant-
Fung, for instance, most of us joined a summer school on 
Quantitative Biology. Other courses, e.g. on proteomics 
or entrepreneurship, are yet to come. Another important 
part of our ITN is the so called “secondments”. A second-
ment can last for 1-6 months and should address one part 
of our research that can be done in the facilities of a part-
ner. The idea behind these secondments is to strengthen 
collaboration and to experience the environments and 
laboratory practices in another lab and institutions. 
Selecting an industrial partner for a secondment provides 
the experience of a different attitude towards research 
and to consider important aspects of research such as 
sustainability or time demand for our research questions.
Besides the numerous positive aspects of a Europe-
wide project we are also aware of the challenge of staying 
connected between multiple locations and keeping up to 
date with the research endeavours of others. With this in 
mind, the consortium meets twice a year. By presenting 
our research at these meetings we stimulate knowledge 
transfer and also ensure staying focused with valuable 
critique and fruitful discussions by sharing and combin-
ing ideas and strategies. This is an essential part of sci-
entific work that we have the opportunity to “practice” 
within a training environment.
Divide and conquer
Our tasks are divided into four work packages, as out-
lined in Fig.  2. Each work package has an independent 
starting point to ensure that each fellow can start their 
research at the time of recruitment. In work package 
one, our aim is to identify novel gene clusters that pro-
duce secondary metabolites in several fungal species. By 
using sequencing technology, we will obtain an inven-
tory of genes potentially useful for secondary metabo-
lite production. An interesting feature of genes involved 
in formation of a secondary metabolite is their clustered 
arrangement in the genome. This makes the identifica-
tion of the genes responsible for metabolite biosynthesis, 
by way of the physical proximity of the genes possible, 
based on searching for key genes such as the non-riboso-
mal-peptide synthetases or the polyketide synthases.
Besides industrial fungal strains with sequenced 
genomes such as Aspergillus spp. or Penicillium spp., 
novel fungal species will be isolated, sequenced and 
potentially explored. One of us (Pradeep Phule) is 
sequencing fungi isolated from marine and terrestrial 
habitats. These uncharacterised species are being inves-
tigated by sequencing their genomes and using computa-
tional tools to identify conserved features in genes which 
are involved in secondary metabolite production.
The gene clusters found with this bioinformatics 
approach will then be expressed in heterologous host 
fungal species in work package two. This is expected to 
lead to a number of novel products, the bioactivities of 
which are to be determined in work package four. In addi-
tion to the sequence data gathered specifically by Quant-
Fung, the emerging genome sequences of fungal strains 
will be explored. For instance, the program will tap into 
the resources of the major effort within this field, being 
the sequencing of 1000 previously unsequenced fungi by 
the Joint Genome Institute (Department of Energy, USA).
The main experiments of work package two are the 
expression of secondary metabolite genes which were 
discovered from genome mining. Genes within second-
ary metabolite clusters will be transferred into Aspergillus 
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niger (Tabea Schütze), Aspergillus nidulans (Benedict 
Dirnberger, Danielle Troppens) or Penicillium chrysoge-
num (Carsten Pohl, Annarita Viggiano) under the control 
of different promoters to drive their expression. In addi-
tion, work package two includes the production of strains 
that can serve as chassis or platform strains. Targeted 
gene replacement or the CRISPR/Cas9 system will be 
used to mutate the genes for the endogenous secondary 
metabolites in the host species. A secondary metabolite-
free strain would allow easier downstream detection and 
purification of the secondary metabolite of interest. To 
boost the expression of genes that are normally silenced, 
we will also use synthetic biology tools that enhance 
transcriptional activation such as the tetracycline induc-
ible tet-system or similar inducible tools. The develop-
ment of modular gene expression systems (Carsten Pohl, 
Tabea Schütze, Yvonne Nygård, Zsófia Büttel, Annarita 
Viggiano) and the study of a new platform to produce 
bioactive substances in specialized fungal cells (Ben-
edict Dirnberger) are two other exciting projects within 
our ITN where we anticipate contributing new tools and 
strategies to the fungal community.
Gene expression and metabolite production need to 
be as efficient as possible. Therefore, work package three 
is focused on systems biology and optimisation of cul-
tivation conditions for secondary metabolite produc-
ers. We will generate metabolome and transcriptome 
data under controlled conditions, e.g. using chemostat 
and batch cultivations. By incorporating these data into 
existing metabolic models for Penicillium spp. (Jens 
Christian Nielsen, Milica Randelovic, Carsten Pohl, Siet-
ske Grijseels, Min Jin Kwon), we want to improve the 
understanding of fluxes within the fungal cell towards 
secondary metabolites and identify key reaction steps to 
focus on further flux modelling and optimisation (Sylvain 
Prigent). Because our project could potentially identify 
interesting compounds that would require synthesis in 
larger quantities for bioactivity screenings or structure 
elucidations, work package three will also produce cul-
tivation protocols for improved secondary metabolite 
production in lab and pilot scale bioreactors (Rafael Diaz, 
Milica Randelovic).
Looking at the three previously described work pack-
ages, a pipeline of steps will ideally lead to the production 
Fig. 1 Locations of the fellows. This map lists the early stage researchers (ESR) and experienced researchers (ER) of our initial training network and 
the city where they are located
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of novel secondary metabolites. However, fast screenings 
of those metabolites for various applications are a pre-
requisite to decide if a certain molecule is of relevance 
for further studies. Thus, work package four addresses 
the bioactivity of secondary metabolites. In work pack-
age four, Annarita Viggiano and Michal Flak will analyse 
the activity of novel secondary metabolites against multi-
drug resistant bacteria (e.g. Pseudomonas aeruginosa, 
Staphylococcus aureus, Klebsiella pneumoniae) and other 
relevant microorganisms (e.g. fungal pathogens like Can-
dida spp.). Together with our industrial partners, we will 
also evaluate the potential for other applications ranging 
from antifungal activity for crop protection to applica-
tions in medicine beyond anti-infective treatments.
Quo Vadis, QuantFung?
What is it that we want to achieve within the next years? 
What should we be aware of for our future careers? What 
contribution do we wish to make with this ITN to soci-
ety? In the following, we share some of our thoughts and 
our ideas on how we see this ITN impacting the fungal 
community and our careers (see also Fig. 3).
We believe that QuantFung could make a substan-
tial contribution to new tools and methods for research 
with filamentous fungi. With our project, we can develop 
new tools and also adapt techniques to fungi from other 
organisms, where synthetic biology tools, metabolic 
modelling and clever strategies for gene expression are 
already established. We would like to stress that the tools 
we develop and the knowledge we generate could also be 
utilised for applications beyond secondary metabolite 
discovery. In our opinion, the potential of filamentous 
fungi for biotechnological production processes is not 
yet fully exploited, perhaps also due to the lack of simple, 
efficient methods and protocols for genetically modifying 
these organisms and to perform straightforward, meta-
bolic engineering.
The public has, in recent years, especially in the EU, 
shown enormous resistance towards growing geneti-
cally modified organisms (in particular crops) for food 
and feed purposes. This, however, seems not to be the 
case for engineered organisms that produce life-sav-
ing drugs such as insulin, other hormones, antibiot-
ics, cholesterol-reducing agents like lovastatin, or the 
Fig. 2 Workflow overview of QuantFung. All work packages can start individually but cooperate and share results in later stages of the project
Page 5 of 6Büttel et al. Fungal Biol Biotechnol  (2015) 2:6 
immunosuppressant cyclosporins that underlies success-
ful organ transplantation. Even though this might be the 
result of these types of molecules not being publically 
discussed at an equal extend as GMOs as food sources, 
we should take the scepticism about genetic modifica-
tions amidst our audience seriously.
Especially when working with unknown isolates and 
strains capable of producing potentially harmful sub-
stances, in the communication with the public we will 
clarify that we are aware of the measures to be taken to 
prevent any harm to humans, other species, and the envi-
ronment. In brief: we are ambassadors of good laboratory 
practice and we regard it as our task to communicate that 
synthetic biology and genetic engineering is sound. We 
should have a concrete idea about the work we do and be 
able to explain how society will benefit from our research. 
Consequently, we would like to contribute to improving 
the acceptance of new, yet safe scientific methods.
Last but not least, when finishing this project 
in 2 or 3  years from now we aim to have gained a 
problem-solving attitude that will help us adapt to new 
challenges and quickly recover from drawbacks. We 
should also keep in mind that establishing and main-
taining a vital network for exchanging ideas about our 
research is most fruitful if it actually leads to collabo-
rations. So, it will require our continuous initiative to 
develop our stories as part of the ITN and to intertwine 
them. In that sense, we envision QuantFung as a cata-
lyst or a platform to ease this kind of cooperation. Ideas, 
visions, and true need for cooperation are essential to 
bring people together. To extend this, we are interested 
in connecting with other current ongoing fungal ITNs, 
namely YeastCell, FungiBrain and ImResFun. Together 
with fellows of YeastCell and FungiBrain, we already held 
a successful symposium in Marburg (Germany) during 
the Annual Meeting of the Association for General and 
Applied Microbiology (VAAM). In addition, during our 
first retreat, a gathering of all QuantFung ESRs and ERs 
in Prague (Czech Republic), we reached out to master 
students at the Charles University and presented our ITN 
Fig. 3 Opinions on the impact of QuantFung. This shows some thoughts on our motivation and why we believe that QuantFung will be a success‑
ful project
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and the Marie-Curie Actions programme. At this occa-
sion, we extended our network again by inviting a fellow 
of ImResFun to introduce his ITN to us and the students.
Thus, the foundations have been laid and the future 
will show how we and this type of initiative will succeed 
in establishing collaborations and a network with fellow 
research groups with expertise in different methods and 
topics. With this in mind, we are convinced that Quant-
Fung is an excellent opportunity to start a research-ori-
ented career in natural sciences.
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